Proteins > Platelet-derived growth factor receptor beta
Page last updated: 2024-08-07 15:40:25
Platelet-derived growth factor receptor beta
A beta-type platelet-derived growth factor receptor that is encoded in the genome of mouse. [OMA:P05622, PRO:DNx]
Synonyms
PDGF-R-beta;
PDGFR-beta;
EC 2.7.10.1;
Beta platelet-derived growth factor receptor;
Beta-type platelet-derived growth factor receptor;
CD140 antigen-like family member B;
Platelet-derived growth factor receptor 1;
PDGFR-1
Research
Bioassay Publications (19)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (36.84) | 18.2507 |
| 2000's | 10 (52.63) | 29.6817 |
| 2010's | 2 (10.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Compounds (27)
Drugs with Inhibition Measurements
Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones.Bioorganic & medicinal chemistry, , Mar-01, Volume: 15, Issue:5, 2007
Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.Journal of medicinal chemistry, , Jun-01, Volume: 49, Issue:11, 2006
Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins.Journal of medicinal chemistry, , May-24, Volume: 39, Issue:11, 1996
A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling.Journal of medicinal chemistry, , Mar-28, Volume: 56, Issue:6, 2013
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer research, , Oct-01, Volume: 64, Issue:19, 2004
Synthesis and structure-activity relationships of 7-substituted 3-(2, 6-dichlorophenyl)-1,6-naphthyridin-2(1H)-ones as selective inhibitors of pp60(c-src).Journal of medicinal chemistry, , Aug-10, Volume: 43, Issue:16, 2000
2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.Journal of medicinal chemistry, , Aug-13, Volume: 41, Issue:17, 1998
Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors.Journal of medicinal chemistry, , May-21, Volume: 41, Issue:11, 1998
Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998
Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.Journal of medicinal chemistry, , Jun-07, Volume: 44, Issue:12, 2001
3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase.Journal of medicinal chemistry, , Nov-02, Volume: 43, Issue:22, 2000
Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.Journal of medicinal chemistry, , Jun-07, Volume: 44, Issue:12, 2001
3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase.Journal of medicinal chemistry, , Nov-02, Volume: 43, Issue:22, 2000
Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors.Journal of medicinal chemistry, , May-21, Volume: 41, Issue:11, 1998
Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.Journal of medicinal chemistry, , Jun-07, Volume: 44, Issue:12, 2001
Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors.Journal of medicinal chemistry, , May-21, Volume: 41, Issue:11, 1998
Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosiJournal of medicinal chemistry, , Mar-27, Volume: 46, Issue:7, 2003
Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases.Journal of medicinal chemistry, , Dec-16, Volume: 42, Issue:25, 1999